Axonics (AXNX)
(Delayed Data from NSDQ)
$70.30 USD
+0.06 (0.09%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $70.33 +0.03 (0.04%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$70.30 USD
+0.06 (0.09%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $70.33 +0.03 (0.04%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth A Momentum C VGM
Zacks News
Are Medical Stocks Lagging Axonics (AXNX) This Year?
by Zacks Equity Research
Here is how Axonics Modulation Technologies (AXNX) and Assertio (ASRT) have performed compared to their sector so far this year.
Here's Why Axonics Modulation Technologies (AXNX) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Axonics Modulation Technologies (AXNX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is Axonics (AXNX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Axonics Modulation Technologies (AXNX) and Dynavax Technologies (DVAX) have performed compared to their sector so far this year.
Axonics Modulation Technologies (AXNX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Axonics (AXNX) delivered earnings and revenue surprises of 17.54% and 16.48%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Is Axonics (AXNX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Axonics Modulation Technologies (AXNX) and DBV Technologies S.A. (DBVT) have performed compared to their sector so far this year.
Has Axonics (AXNX) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Axonics Modulation Technologies (AXNX) and Bellus Health (BLU) have performed compared to their sector so far this year.
Zacks Industry Outlook Highlights Omnicell, Axonics and Outset Medical
by Zacks Equity Research
Omnicell, Axonics and Outset Medical have been highlighted in this Industry Outlook article.
3 Medical Info System Stocks Braving Industry Headwinds
by Urmimala Biswas
Medical Info Systems stocks like Omnicell, Inc. (OMCL), Axonics, Inc. (AXNX) and Outset Medical, Inc. (OM) are expected to gain despite pandemic-led disruptions.
Axonics Modulation Technologies (AXNX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Axonics (AXNX) delivered earnings and revenue surprises of 27.54% and 7.69%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Signify Health (SGFY) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Signify (SGFY) delivered earnings and revenue surprises of 266.67% and 3.23%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Axonics Modulation Technologies (AXNX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Axonics (AXNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
iRhythm Technologies (IRTC) Soars 4.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
iRhythm Technologies (IRTC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Axonics Modulation Technologies (AXNX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Axonics (AXNX) delivered earnings and revenue surprises of 5.56% and 6.70%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
IRhythm Technologies (IRTC) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
iRhythm Technologies (IRTC) delivered earnings and revenue surprises of 9.84% and 4.61%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Axonics Modulation Technologies (AXNX) Q4 Earnings Expected to Decline
by Zacks Equity Research
Axonics (AXNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Omnicell (OMCL) Lags Q4 Earnings Estimates
by Zacks Equity Research
Omnicell (OMCL) delivered earnings and revenue surprises of -3.16% and 0.30%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Axonics (AXNX) Soars 7.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Axonics (AXNX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Axonics Modulation Technologies (AXNX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Axonics (AXNX) delivered earnings and revenue surprises of 17.39% and -3.83%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Axonics Modulation Technologies (AXNX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Axonics (AXNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Axonics Modulation Technologies (AXNX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Axonics (AXNX) delivered earnings and revenue surprises of -15.69% and 16.89%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Axonics Modulation Technologies (AXNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Axonics (AXNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Axonics Modulation Technologies (AXNX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Axonics (AXNX) delivered earnings and revenue surprises of -12.20% and 23.40%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Axonics Modulation Technologies (AXNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Axonics (AXNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the SPDR SP Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
Axonics Modulation Technologies (AXNX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Axonics (AXNX) delivered earnings and revenue surprises of 53.85% and 60.15%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?